Comparing the Efficacy of Nab-PH+Pyrrolitinib and TCbHP in the Neoadjuvant Treatment of HER2 Positive BC

PHASE2RecruitingINTERVENTIONAL
Enrollment

610

Participants

Timeline

Start Date

May 3, 2023

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2026

Conditions
Breast CancerHER2-positive Breast Cancer
Interventions
DRUG

Albumin paclitaxel+trastuzumab+pyrrolitinib

albumin paclitaxel (260mg/㎡ every 3 weeks or 125mg/㎡ weekly)+trastuzumab (initial loading dose 8 mg/kg, sequential maintenance dose 6 mg/kg, once every 3 weeks)+pyrrolitinib (320mg, QD), 3 weeks as one cycle.

DRUG

Docetaxel+Carboplatin+trastuzumab+Parstuzumab

Docetaxel 75 mg/m2+carboplatin (AUC=6)+trastuzumab (initial loading dose 8 mg/kg, sequential maintenance dose 6 mg/kg)+patuzumab (initial loading dose 840mg, sequential maintenance dose 420 mg), one cycle every 21 days

Trial Locations (1)

Unknown

RECRUITING

Henan cancer hospital, Zhengzhou

All Listed Sponsors
lead

Henan Cancer Hospital

OTHER_GOV